Clinical trials: Glucagon
Type 2 Diabetes Mellitus
Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)
The primary objectives of this study are to determine if sitagliptin treatment is not inferior to that of glimepiride as measured by the change in baseline hemoglobin A1C (HbA1C) after 30 weeks of treatment, and if sitagliptin…
- Trial name
- NCT01189890
- Testing
- sitagliptin phosphate, Glimepiride
- Volunteers
- 480 people
- Sponsor
- Merck Sharp & Dohme LLC
Insulin Secretion, Insulin Resistance
Contribution of Pancreatic αcells Function to Blood Glucose Regulation in Chinese Type 2 Diabetics- the Effect of Sitagliptin on Glucagon Secretion, Insulin Secretion and Insulin Resistance in Chinese Type 2 Diabetics
1. The purpose of this study is to determine whether Sitagliptin therapy suppress glucagon release and improve glucose control in Chinese type 2 diabetic. 2.
- Trial name
- NCT01610154
- Testing
- Sitagliptin
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Guangwei Li
Diabetes Mellitus
Integration of Continuous Glucose Monitoring Into a BiHormonal Closed-Loop Artificial Pancreas
The investigators hypothesize that our closed-loop glucose-control system can provide BG control in subjects with type 1 diabetes using the estimated BG signal from a CGM as the input signal to the controller.
- Trial name
- CL2 (NCT01161862)
- Testing
- Bi-hormonal (insulin and glucagon) artificial pancreas
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Boston University Charles River Campus
Irritable Bowel Syndrome Constipation Predominant
Effects of ROSE-010 on GI Transit in Constipation Predominant Irritable Bowel Syndrome (C-IBS) Patients
This trial will study the effects of an investigational (not FDA approved) medication, ROSE-010, on the movement of food through the stomach, small intestine and colon in females with constipation predominant irritable bowel…
- Trial name
- NCT01056107
- Testing
- ROSE-010
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Mayo Clinic
Hypoglycemia, Complications of Bariatric Procedures
Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery Patients
The primary objective of this study is to test an optimized control system for sensor-guided (physician administered) delivery of glucagon, and test Proof-of-Concept (POC) in a clinical setting in patients with severe…
- Trial name
- NCT02733588
- Testing
- G-Pump™ (glucagon infusion)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Xeris Pharmaceuticals
Diabetes Mellitus, Type 2
Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA
This is a multi-center, randomised, double-blind, parallel-group, safety and efficacy study of empagliflozin as add-on to GLP-1 RA in Japanese patients with Type 2 Diabetes Mellitus with insufficient glycaemic control
- Trial name
- NCT02589626
- Testing
- empagliflozin 10mg, empagliflozin 25 mg
- Where
- 16 sites in Japan
- Volunteers
- 65 people
- Sponsor
- Boehringer Ingelheim
Pre-diabetes, Type 2 Diabetes
Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass
This study evaluates exenatide, sitagliptin, and glimepiride for the treatment of high blood sugar in patients with impaired fasting glucose or early type 2 diabetes.
- Trial name
- NCT00775684
- Testing
- Exenatide, Sitagliptin, Glimepiride
- Where
- 3 sites in United States
- Volunteers
- 47 people
- Sponsor
- University of Pennsylvania
Hypoglycemia, Diabetes Mellitus, Type 1
Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM
A randomized, double-blind, parallel-group trial to confirm the clinical efficacy and safety of dasiglucagon in the rescue treatment of hypoglycemia in subjects with type 1 diabetes mellitus (T1DM) compared to placebo
- Trial name
- NCT03688711
- Testing
- Dasiglucagon
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Zealand Pharma
Type 2 Diabetes
Sitagliptin and Glucagon Counterregulation
To evaluate the effect of DPP-4 inhibition on glucagon counter-regulatory mechanisms at moderate hypoglycemia in metformin-treated subjects with T2DM
- Trial name
- SITACLAMP (NCT02256189)
- Testing
- Sitagliptin
- Where
- Sweden
- Volunteers
- 28 people
- Sponsor
- Lund University
Type 2 Diabetes
Vildagliptin Versus Dapagliflozin on Glucagon
The aim of the study is to assess if vildagliptin and dapagliflozin have dissociated effects on glucagon secretion after a mixed meal ingestion in metformin-treated subjects with type 2 diabetes and whether this is associated…
- Trial name
- NCT02475070
- Testing
- Vildagliptin, Dapagliflozin
- Where
- Sweden
- Volunteers
- 28 people
- Sponsor
- Lund University
Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
The goal for this study is to evaluate the efficacy and safety of tirzepatide versus placebo in participants with type 2 diabetes not under control with diet and exercise alone.
- Trial name
- SURPASS-1 (NCT03954834)
- Testing
- Tirzepatide
- Where
- 53 sites in United States, India and 3 more
- Volunteers
- 478 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria
Research Design/Plan: After screening, each subject will receive 1 measurements of Endogenous Glucose Production [EGP] with prime-continuous Infusion of 3-3H-glucose.
- Trial name
- NCT03331289
- Testing
- Exenatide, Dapagliflozin, Exenatide and Dapagliflozin
- Where
- United States
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Diabetes Mellitus, Type 1
Mini-Dose Glucagon to Treat Non-Severe Hypoglycemia
The purpose of this study is to determine if a small dose of glucagon (mini-dose glucagon) is effective for the treatment of non-severe hypoglycemia in adults with type 1 diabetes (T1D).
- Trial name
- NCT02411578
- Testing
- G-Pen Mini™ (glucagon injection), Glucose Tablets
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Jaeb Center for Health Research
Hypoglycemia, Diabetes Mellitus
Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents
Up to fifty (50) children and adolescents with type 1 diabetes (T1D) aged 4 to ˂18 years at time of enrolment will be selected for inclusion in the study.
- Trial name
- NCT02402933
- Testing
- Nasal Glucagon
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus
Effect of Ethanol Intoxication on the Anti-Hypoglycemic Action of Glucagon
This study will test the hypothesis that a BAC (blood alcohol content) of 0.1% will not significantly alter the anti-hypoglycemic effect of mico-dose glucagon in individuals with type 1 diabetes.
- Trial name
- NCT02516150
- Testing
- Ethanol, Glucagon
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Massachusetts General Hospital
Type 1 Diabetes Mellitus
Safety Study of Repeated Doses of Glucagon on Animal Starch in the Liver
The purpose of this study is to learn if giving multiple doses of a hormone called glucagon can cause a major decrease in liver glycogen (animal starch).
- Trial name
- NCT01986231
- Testing
- Glucagon
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Legacy Health System
Type 1 Diabetes
Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone
This study aims to test an insulin and glucagon delivery algorithm designed to be used in conjunction with a continuous glucose monitoring system.
- Trial name
- NCT00797823
- Testing
- Insulin, Asp(B28)-, Glucagon
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Legacy Health System
Short Bowel Syndrome
Short Bowel Syndrome and Teduglutide Versus Placebo
This research study was done to see what the effects are of Teduglutide on people with short bowel syndrome (SBS). Teduglutide is a synthetic medication administered as an injection, which has shown to increase intestinal blood…
- Trial name
- NCT02099084
- Testing
- Teduglutide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Mayo Clinic
Hypoglycemia, Diabetes Mellitus
Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia
Up to two hundred (200) adult participants with type 1 diabetes (T1D) aged 18 to 75 years will be selected for inclusion in the study.
- Conditions
- Hypoglycemia, Diabetes Mellitus, Drug-Specific Antibodies
- Trial name
- NCT02171130
- Testing
- Nasal Glucagon
- Where
- 9 sites in United States, Canada
- Volunteers
- 129 people
- Sponsor
- Eli Lilly and Company
Diabetic Kidney Disease
The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease
Diabetic kidney disease (DKD) is a devastating complication of diabetes, that in it's worst form, can lead to early cardiovascular death or kidney failure.
- Trial name
- NCT01847313
- Testing
- Liraglutide
- Where
- Ireland
- Volunteers
- 20 people
- Sponsor
- Karl Neff